Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma PatientsRecruiting
NCT02622581N/AUpdated Feb 18, 2025
Sponsor: AIO-Studien-gGmbH
Metastatic Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer Metastatic · Non-small Cell Lung Cancer Stage II · Non Small Cell Lung Cancer Stage III
Germany
Stage III NSCLC RWE in Chinese PatientsCompleted
NCT04023812N/AUpdated Feb 18, 2025
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
China
Tezepelumab COPD Exacerbation StudyCompleted
NCT04039113Phase 2Updated Feb 18, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Canada, Denmark, France, Germany +5 more
Olaparib for PAH: a Multicenter Clinical TrialTerminated
NCT03782818Phase 1, Phase 2Updated Feb 12, 2025
Sponsor: Laval University
Pulmonary Arterial Hypertension
Canada
TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary CauseCompleted
NCT06172751N/AUpdated Feb 12, 2025
Sponsor: AstraZeneca
Hypereosinophilic Syndrome (HES)
United States
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination DeficiencyWithdrawn
NCT06120972Phase 2Updated Feb 12, 2025
Sponsor: Alexander B Olawaiye, MD
Ovarian Cancer
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung CancersCompleted
NCT04230408Phase 2Updated Feb 11, 2025
Sponsor: Latin American Cooperative Oncology Group
Lung Neoplasms
Brazil
Osimertinib for NSCLC With EGFR Exon 20 Insertion MutationCompleted
NCT03414814Phase 2Updated Feb 11, 2025
Sponsor: Seoul National University Hospital
Locally Advanced or Metastatic NSCLC
South Korea
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780Completed
NCT06576765Phase 1Updated Feb 10, 2025
Sponsor: AstraZeneca
Hepatic Impairment
United States
A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the KneeCompleted
NCT04675034Phase 2Updated Feb 10, 2025
Sponsor: AstraZeneca
Painful Osteoarthritis of the Knee
Denmark, Estonia, Germany, Poland, Spain +1 more
A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing PotentialCompleted
NCT06657105Phase 1Updated Feb 7, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)Completed
NCT05780437Phase 3Updated Feb 4, 2025
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
United States, Denmark, Greece, Poland, Singapore +4 more
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian CancerCompleted
NCT00753545Phase 2Updated Feb 3, 2025
Sponsor: AstraZeneca
Ovarian Cancer
United States, Australia, Austria, Belgium, Canada +12 more
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active Not Recruiting
NCT03944772Phase 2Updated Jan 30, 2025
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Denmark, Italy, Japan, Netherlands +4 more
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate CancerTerminated
NCT05501548Phase 2Updated Jan 29, 2025
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer · Castration-resistant Prostate Cancer
United States
A Study to Evaluate Guideline Adoption Through Quality Improvement Project (QIP) in Pulmonary and Critical Care Medicine (PCCM) DepartmentNot Yet Recruiting
NCT06484972N/AUpdated Jan 28, 2025
Sponsor: China-Japan Friendship Hospital
Lung Cancer
Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790MCompleted
NCT02841579Phase 2Updated Jan 28, 2025
Sponsor: MedSIR
Non-Small Cell Lung Cancer
Spain
EU Secondary Data Post-Authorisation Safety Study of AZD1222Completed
NCT05126992N/AUpdated Jan 28, 2025
Sponsor: AstraZeneca
COVID-19, Vaccine Adverse Events of Special Interest
Netherlands, Spain, United Kingdom
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerCompleted
NCT03523572Phase 1Updated Jan 27, 2025
Sponsor: Daiichi Sankyo
Breast Cancer · Urothelial Carcinoma
United States, Belgium, France, Germany, Italy +2 more
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised AdultsTerminated
NCT05057897Phase 4Updated Jan 27, 2025
Sponsor: AstraZeneca
COVID-19, SARS-CoV-2
Thailand, Ukraine
Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate CancersActive Not Recruiting
NCT00223171Phase 3Updated Jan 27, 2025
Sponsor: Université de Sherbrooke
Prostate Cancer
Canada
Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy AloneActive Not Recruiting
NCT00223145Phase 3Updated Jan 27, 2025
Sponsor: Abdenour Nabid
Prostate Cancer
Canada
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)Active Not Recruiting
NCT05348577Phase 3Updated Jan 27, 2025
Sponsor: AstraZeneca
Prostate Cancer
United States, Australia, Belgium, Brazil, Canada +17 more
A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast CancerCompleted
NCT04588298Phase 2Updated Jan 24, 2025
Sponsor: AstraZeneca
HER2-negative Breast Cancer
Georgia, Mexico, United Kingdom
Zoladex® 10.8 BC RWSCompleted
NCT05184257N/AUpdated Jan 23, 2025
Sponsor: AstraZeneca
Breast Cancer
China

Previous page Next page